Therapy for the treatment of disease
Disclosed herein are pharmaceutical compositions comprising oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition.
1. A pharmaceutical composition comprising a therapeutically effective amount of oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof,
wherein the oxybutynin and pilocarpine are formulated such that the peak saliva flow time point for pilocarpine occurs at nearly the same time as the lowest saliva flow time point for oxybutynin.
2. The pharmaceutical composition of claim 1 , further comprising a pharmaceutically acceptable carrier, diluent, or excipient.
3. The pharmaceutical composition of claim 1 , wherein the oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of between 1 mg to 30 mg.
4. The pharmaceutical composition of claim 1 , wherein the oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of 5 mg.
5. The pharmaceutical composition of claim 1 , wherein the oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of 10 mg.
6. The pharmaceutical composition of claim 1 , wherein the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of between 1 mg to 30 mg.
7. The pharmaceutical composition of claim 1 , wherein the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of 5 mg.
8. The pharmaceutical composition of claim 1 , wherein the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of 10 mg.
9. The composition of claim 1 , wherein pilocarpine is released between about 30 minutes to about 60 minutes after oxybutynin is released.
10. The composition of claim 1 , wherein pilocarpine is released about 30 minutes after oxybutynin is released.
11. A pharmaceutical composition comprising a dose of oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, in the range of between 1 mg to 30 mg, in combination with a dose of pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, in the range of between 1 mg to 30 mg,
wherein the oxybutynin and pilocarpine are formulated such that the peak saliva flow time point for pilocarpine occurs at nearly the same time as the lowest saliva flow time point for oxybutynin.
12. The pharmaceutical composition of claim 11 , wherein the oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of 5 mg.
13. The pharmaceutical composition of claim 11 , wherein the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of 5 mg.
14. The pharmaceutical composition of claim 11 , wherein the oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of 10 mg.
15. The pharmaceutical composition of claim 11 , wherein the pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, is present in a dose of 10 mg.
16. The composition of claim 11 , wherein pilocarpine is released between about 30 minutes to about 60 minutes after oxybutynin is released
17. The composition of claim 11 , wherein pilocarpine is released about 30 minutes after oxybutynin is released.
18. A pharmaceutical composition comprising 5 mg of oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, in combination with 5 mg of pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof,
wherein the oxybutynin and pilocarpine are formulated such that the peak saliva flow time point for pilocarpine occurs at nearly the same time as the lowest saliva flow time point for oxybutynin.
19. The composition of claim 18 , wherein pilocarpine is released between about 30 minutes to about 60 minutes after oxybutynin is released.
20. The composition of claim 18 , wherein pilocarpine is released about 30 minutes after oxybutynin is released.